A Phase 2/3 interventional study of rapamycin and placebo in Facial Angiofibroma and Tuberous Sclerosis, sponsored by Dermatology Specialties Limited Partnership. Completed at 17 sites in 9 countries. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-08.
Sponsored by Dermatology Specialties Limited Partnership · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing sirolimus in Tuberous Sclerosis — 1 open to participants now, 2 under way, 1 of them phase 3. Sirolimus · Tuberous Sclerosis.
Among the 12 studies testing sirolimus in Tuberous Sclerosis, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 2 in phase 2/3, and was the 9th registered.
115 studies on the registry are indexed under Tuberous Sclerosis; 27 are open to participants now.
Browse Tuberous Sclerosis studies →1 of the 12 studies testing sirolimus in Tuberous Sclerosis is open now, in 1 country. Recruiting first, the newest first:
Katarzyna Kotulska · Sites in Poland
Ages 4 wk–16 wk
By country, each count listing its studies:
Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 21 Tuberous Sclerosis studies recruiting now, 10 (48%) set no upper age limit and 8 (38%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 6 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 52 across 73 interventional studies indexed under Tuberous Sclerosis.
Median enrollment 31 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dermatology Specialties Limited Partnership as lead sponsor.
Dermatology Specialties Limited Partnership has 1 study filed under Tuberous Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing sirolimus in Tuberous Sclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05104983Darcy KruegerStopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing sirolimus in Tuberous Sclerosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to compare the safety and efficacy of two different strengths of Rapamycin cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (FA) associated with Tuberous Sclerosis Complex (TSC).
Topical rapamycin has previously been used to treat FA associated with TSC, reducing erythema, papule size, while flattening lesions and improving skin texture. Topical rapamycin has been reported to be well tolerated.
The efficacy and safety of a topical rapamycin cream at two strengths (0.5% and 1.0%) will be assessed during a 26 week double-blind treatment phase with assessments made at clinical visits at baseline, 2, 8, 14, 20 and 26 weeks, and at follow-up (4 weeks after the last dose of study drug).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
Drug: rapamycin
Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
Drug: rapamycin
Placebo cream topical, applied once daily before bed on affected area for 26 weeks
Drug: placebo
Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
Also known as: sirolimus
Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
Percentage of Participants Obtaining Successful Treatment
Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe
Time frame: After 26 weeks treatment
Time to Treatment Success
The time elapsed from the first dose to the time of treatment success, according to the Investigator's Global Assessment (IGA) scale. The total time of treatment was 26 weeks, although Covid-19 visit delays led to an extension of up to 2 weeks (28 weeks total) for some patients. Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe
Time frame: From first dose to 26 weeks (± 2 weeks)
Change From Baseline in Investigator's Global Assessment
The change in grading on the Investigator's Global Assessment (IGA) scale from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe
Time frame: At baseline and after 26 weeks treatment
Change From Baseline in Facial Angiofibroma Severity Index (FASI)
The change in grading on the Facial Angiofibroma Severity Index (FASI) from baseline. FASI grades lesions according to their erythema, size and extent by summing the scores of each category. The final FASI scores range from (mild) 2-9 (severe). Erythema Skin color 0 Light Red 1 Red 2 Dark Red/purple 3 Size None 0 Small (\< 5mm) 1 Large (\> 5mm) 2 Confluent 3 Extension \<50 % cheek surface 2 \>50% cheek surface 3
Time frame: At baseline and after 26 weeks treatment
Subjective (Participant or Parent/Caregiver) Percentage Change Rating Scale
Percentage change in facial angiofibroma since beginning treatment, as assessed by the participant or parent/caregiver. A large value indicates most improvement to facial angiofibroma (minimum=0, maximum=100). This was a single assessment time-point, where the participant or parent/caregiver estimated the percentage change in the facial angiofibroma lesion appearance from their perspective since baseline.
Time frame: After 26 weeks treatment
Objective (Clinician) Percentage Change Rating Scale
Percentage improvement in facial angiofibroma since beginning treatment, as assessed by the clinician. A large value indicates most improvement to facial angiofibroma (minimum=0, maximum=100). This was a single assessment time-point, where clinicians estimated the percentage change in the facial angiofibroma lesion appearance from their perspective since baseline.
Time frame: After 26 weeks treatment
Categorical Change in Facial Angiofibroma
Change in facial angiofibroma since beginning treatment on a 5-point scale, as assessed by the participant or parent/caregiver. This was a single assessment time-point, where the participant or parent/caregiver evaluated the change in the facial angiofibroma lesion appearance from their perspective since baseline.
Time frame: After 26 weeks treatment
| Milestone | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| Started | 36 | 33 | 38 |
| Completed | 32 | 31 | 35 |
| Not completed | 4 | 2 | 3 |
Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe
| Participants | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| Percentage of Participants Obtaining Successful Treatment | 4 | 3 | 2 |
The time elapsed from the first dose to the time of treatment success, according to the Investigator's Global Assessment (IGA) scale. The total time of treatment was 26 weeks, although Covid-19 visit delays led to an extension of up to 2 weeks (28 weeks total) for some patients. Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe
| weeks | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| Time to Treatment Success | 25.89 ± 0.7 | 26.71 ± 0.28 | 19.7 ± 0.22 |
The change in grading on the Investigator's Global Assessment (IGA) scale from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe
| Participants | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| -2 | 4 | 3 | 2 |
| -1 | 16 | 17 | 7 |
| 0 | 15 | 13 | 28 |
| +1 | 0 | 0 | 1 |
| Missing | 1 | 0 | 0 |
The change in grading on the Facial Angiofibroma Severity Index (FASI) from baseline. FASI grades lesions according to their erythema, size and extent by summing the scores of each category. The final FASI scores range from (mild) 2-9 (severe). Erythema Skin color 0 Light Red 1 Red 2 Dark Red/purple 3 Size None 0 Small (\< 5mm) 1 Large (\> 5mm) 2 Confluent 3 Extension \<50 % cheek surface 2 \>50% cheek surface 3
| Participants | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| -5 | 1 | 1 | 0 |
| -4 | 1 | 3 | 1 |
| -3 | 6 | 3 | 1 |
| -2 | 10 | 9 | 3 |
| -1 | 10 | 13 | 17 |
| 0 | 7 | 4 | 14 |
| +1 | 0 | 0 | 1 |
| +2 | 0 | 0 | 1 |
| Missing | 1 | 0 | 0 |
Percentage change in facial angiofibroma since beginning treatment, as assessed by the participant or parent/caregiver. A large value indicates most improvement to facial angiofibroma (minimum=0, maximum=100). This was a single assessment time-point, where the participant or parent/caregiver estimated the percentage change in the facial angiofibroma lesion appearance from their perspective since baseline.
| Percentage Change | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| Subjective (Participant or Parent/Caregiver) Percentage Change Rating Scale | 57.06 ± 4.36 | 54.06 ± 5.21 | 30.84 ± 3.89 |
Percentage improvement in facial angiofibroma since beginning treatment, as assessed by the clinician. A large value indicates most improvement to facial angiofibroma (minimum=0, maximum=100). This was a single assessment time-point, where clinicians estimated the percentage change in the facial angiofibroma lesion appearance from their perspective since baseline.
| Percentage Change | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| Objective (Clinician) Percentage Change Rating Scale | 47.83 ± 3.88 | 49.39 ± 5.22 | 20.76 ± 4.05 |
Change in facial angiofibroma since beginning treatment on a 5-point scale, as assessed by the participant or parent/caregiver. This was a single assessment time-point, where the participant or parent/caregiver evaluated the change in the facial angiofibroma lesion appearance from their perspective since baseline.
| Participants | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| -1 - Worse | 1 | 0 | 0 |
| 0 - No Difference | 0 | 1 | 12 |
| +1 - Slightly Better | 2 | 7 | 11 |
| +2 - Moderately Better | 13 | 7 | 9 |
| +3 - Significantly Better | 16 | 13 | 4 |
| Missing | 4 | 5 | 2 |
Collected over 30 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5% Rapamycin Cream, Topical | 0/36 (0%) | 2/36 (5.6%) | 29/36 (80.6%) |
| 1.0% Rapamycin Cream, Topical | 0/33 (0%) | 2/33 (6.1%) | 27/33 (81.8%) |
| Placebo | 0/38 (0%) | 2/38 (5.3%) | 27/38 (71.1%) |
| Event | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| Constipation, nausea, malnutrition, diarrheaGastrointestinal disorders | 0/36 | 0/33 | 2/38 |
| Kidney bleedingRenal and urinary disorders | 0/36 | 1/33 | 0/38 |
| Collapsed lungInjury, poisoning and procedural complications | 0/36 | 1/33 | 0/38 |
| SeizureNervous system disorders | 1/36 | 0/33 | 1/38 |
| Chest painCardiac disorders | 1/36 | 0/33 | 0/38 |
| Supraventricular tachycardiaCardiac disorders | 0/36 | 0/33 | 1/38 |
| Event | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 9/36 | 12/33 | 2/38 |
| Skin burning sensationSkin and subcutaneous tissue disorders | 13/36 | 6/33 | 5/38 |
| ErythemaSkin and subcutaneous tissue disorders | 7/36 | 6/33 | 4/38 |
| Dry SkinSkin and subcutaneous tissue disorders | 7/36 | 5/33 | 0/38 |
| Pain of skinSkin and subcutaneous tissue disorders | 3/36 | 4/33 | 2/38 |
| SeizureNervous system disorders | 2/36 | 4/33 | 0/38 |
| AcneSkin and subcutaneous tissue disorders | 2/36 | 3/33 | 2/38 |
| HaemorrhageVascular disorders | 2/36 | 3/33 | 2/38 |
| Upper respiratory tract infectionInfections and infestations | 0/36 | 0/33 | 3/38 |
| RhinitisInfections and infestations | 1/36 | 2/33 | 0/38 |
| Age, Continuous(years) | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo | Total |
|---|---|---|---|---|
| Mean | 27.8 ± 15 | 25.5 ± 15 | 26.3 ± 13.8 | 26.6 ± 14.5 |
| Age, Customized(Participants) | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo | Total |
|---|---|---|---|---|
| Age group — 6-11 years | 6 | 4 | 6 | 16 |
| Age group — 12-17 years | 5 | 8 | 7 | 20 |
| Age group — 18-65 years | 25 | 21 | 25 | 71 |
| Sex: Female, Male(Participants) | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo | Total |
|---|---|---|---|---|
| Female | 21 | 14 | 23 | 58 |
| Male | 15 | 19 | 15 | 49 |
| Ethnicity (NIH/OMB)(Participants) | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 4 | 13 |
| Not Hispanic or Latino | 31 | 29 | 34 | 94 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 7 | 5 | 6 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 28 | 26 | 30 | 84 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Study Site(Participants) | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo | Total |
|---|---|---|---|---|
| Site #00 - ACRI Johns Hopkins | 0 | 0 | 2 | 2 |
| Site #01 - University Hospital Brno | 1 | 0 | 0 | 1 |
| Site #02 - Children's Health Queensland | 1 | 1 | 0 | 2 |
| Site #03 - Christchurch Hospital | 2 | 2 | 3 | 7 |
| Site #04 - University of Navarra | 4 | 4 | 3 | 11 |
| Site #05 - Mayo Clinic | 1 | 0 | 1 | 2 |
| Site #06 - Phoenix Children's Hospital | 2 | 2 | 1 | 5 |
| Site #07 - Spectrum Health, Michigan | 3 | 3 | 3 | 9 |
| Site #08 - University of California, San Diego | 3 | 4 | 2 | 9 |
| Site #09 - University of Virginia | 1 | 0 | 1 | 2 |
| Site #10 - University of Pecs | 1 | 1 | 2 | 4 |
| Site #11 - Slovakia National Institute of Children's Diseases | 3 | 2 | 2 | 7 |
| Site #12 - Bethesda Children's Hospital | 5 | 4 | 7 | 16 |
| Site #13 - University of Szeged | 0 | 0 | 0 | 0 |
| Site #14 - Clinic of Neurology and Psychiatry for Children and Youth, Belgrade | 2 | 3 | 3 | 8 |
| Site #15 - Clinical Center of Serbia | 2 | 2 | 3 | 7 |
| Site #16 - National Taiwan University | 5 | 5 | 5 | 15 |
| Height(centimeters) | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo | Total |
|---|---|---|---|---|
| Mean | 164 ± 17 | 165 ± 16 | 161 ± 17 | 163 ± 17 |
| Weight(kilograms) | 0.5% Rapamycin Cream, Topical | 1.0% Rapamycin Cream, Topical | Placebo | Total |
|---|---|---|---|---|
| Mean | 68.1 ± 22.8 | 68.9 ± 24.3 | 68.4 ± 25.8 | 68.5 ± 24.2 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual Participant Data is not planned to be shared with other researchers
Ran from Jul 2019 to primary completion in Sep 2022, 37 months.
Results were first posted in Aug 2023, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus